Therapeutic Effect of Isogladine Maleate on Small Intestinal Mucosal Injury Associated With NSAIDS in Population

PHASE4UnknownINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

August 31, 2022

Study Completion Date

April 30, 2023

Conditions

NSAIDs-associated Intestinal Mucosal Injury

Interventions

DRUG

Irsogladine Maleate

Orally administration of irsogladine maleate 4mg/day, for 8 weeks.

DRUG

Hydrotalcite

Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.